Altimmune, Inc. - ALT STOCK NEWS

Altimmune, Inc. (Nasdaq: ALT) has successfully completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic targeting chronic hepatitis B (CHB). This trial involves approximately 80 subjects across 26 sites in North America, Europe, and Southeast Asia. The primary endpoint is a significant reduction in hepatitis B surface antigen (HBsAg). The data readout is anticipated in Q1 2024. HepTcell, which combines nine synthetic peptides with an adjuvant, aims to provoke immune responses against HBV. Given the disease’s global impact, affecting around 296 million people and resulting in over 800,000 deaths annually, this trial may pave the way toward a functional cure for CHB. Additionally, Altimmune is set to initiate a Phase 2b trial for non-alcoholic steatohepatitis (NASH) in mid-2023, with key data from an obesity trial expected in late 2023.

Altimmune, Inc. (Nasdaq: ALT) has appointed Catherine Angell Sohn, Pharm.D., to its Board of Directors, effective March 27, 2023. Her extensive experience in pharmaceutical product development and commercialization is expected to benefit Altimmune’s mission to create next-generation peptide therapeutics for obesity and liver diseases. Currently an independent director at Jazz Pharmaceuticals and Axcella Health, Dr. Sohn previously held strategic roles at GlaxoSmithKline, driving significant acquisitions and launches. She aims to support Altimmune’s clinical pipeline, which includes pemvidutide for obesity and HepTcell™ for chronic hepatitis B.

Altimmune announced the MOMENTUM Phase 2 obesity trial results, reporting a mean weight loss of 10.7% at the 2.4 mg dose after 24 weeks, with 50% of subjects achieving 10% or more weight loss. Significantly, subjects under 115 kg achieved a mean weight loss of 11.9%. Improvements in waist circumference, serum lipids, and blood pressure were also noted without significant heart rate changes. The Phase 1b safety trial for Type 2 diabetes showed 7.7% weight loss at the same dose. Adverse events were similar to earlier trials, primarily gastrointestinal.

Altimmune, Inc. (NASDAQ: ALT) announced its Q4 and full-year 2022 financial results on February 28, 2023, highlighting critical upcoming milestones in its clinical trials. The interim 24-week readout from the MOMENTUM Phase 2 obesity trial is expected in March 2023, while a Phase 2b trial for non-alcoholic steatohepatitis (NASH) will kick off mid-2023. Notable achievements include a 75% reduction in liver fat observed in NAFLD trials and a net loss of $21.7 million for Q4 2022, a decrease from $23.9 million in Q4 2021. The company holds $184.9 million in cash as of December 31, 2022.

Altimmune, Inc. (Nasdaq: ALT) announced plans to report its fourth quarter and full year 2022 financial results on February 28, 2023. The company will also provide a business update during the conference call scheduled for 8:30 AM ET that day. The call will be accessible via their Investor Relations website. Altimmune focuses on developing novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), targeting obesity and NASH. Additionally, the company is working on HepTcell™, aimed at chronic hepatitis B treatment.

Altimmune, Inc. has appointed Raymond Jordt as the new Chief Business Officer, effective January 1, 2023. He succeeds José Ochoa, who is leaving for other opportunities. Jordt brings over 25 years of pharmaceutical experience, most recently with Eli Lilly, where he held various roles, including Head of Transactions. Under his leadership, significant portfolio transformations occurred. CEO Vipin Garg expressed optimism about Jordt's expertise aiding the clinical development of the company's key candidates, pemvidutide and HepTcell, targeting obesity, NASH, and hepatitis B.

Altimmune, Inc. announced that Dr. Stephen A. Harrison will present results from the 12-week Phase 1b and subsequent extension trials of pemvidutide for non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference on January 7, 2023. Pemvidutide, a dual receptor agonist for obesity and NASH, showed significant reductions in liver fat and body weight. The company is focused on the development of innovative therapeutic solutions targeting liver diseases and obesity, with pemvidutide being a key candidate.

Altimmune has reported positive topline results from a 24-week trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). At doses of 1.8 mg and 2.4 mg, participants achieved significant reductions in liver fat content, with over 75% relative decrease observed. The trial also reported notable declines in serum alanine aminotransferase and improved glycemic control. Weight loss averages reached 7.2% for non-diabetic subjects. Pemvidutide showed a favorable safety profile, with mostly mild adverse events. The results suggest potential for advancement to Phase 2b trials for NAFLD.

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), will participate in two upcoming investor conferences. The first is the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, featuring a fireside chat at 10:55 am ET. The second is the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, with a fireside chat at 10:00 am ET. Both sessions will be accessible via webcast on Altimmune's website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with notable products like pemvidutide (ALT-801).